-
Patent Agency Ranking
公开(公告)号：US20110318373A1
公开(公告)日：2011-12-29
申请号：US13168453
申请日：2011-06-24
Applicant: Pottayil G. N. Sasikumar , Muralidhara Ramachandra , Suresh K. Vadlamani , Koteswara R. Vemula , Leena K. Satyam , Krishnaprasad Subbarao , K R. Shrimali , Sreenivas Kandepu
Inventor： Pottayil G. N. Sasikumar , Muralidhara Ramachandra , Suresh K. Vadlamani , Koteswara R. Vemula , Leena K. Satyam , Krishnaprasad Subbarao , K R. Shrimali , Sreenivas Kandepu
IPC: A61K39/00 , A61P35/00 , A61P31/00 , A61K38/10 , A61P35/04 , A61P35/02 , A61P31/04 , A61P31/12 , C07K14/435 , A61P37/02
CPC classification number: C07K14/705 , A61K38/00 , Y02A50/409 , Y02A50/411 , Y02A50/463
Abstract: The present invention provides immunosuppression compounds capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The present invention further provides peptide based compositions for treatment of cancer or treatment of infections via immunopotentiation caused by inhibition of immunosuppressive signaling induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient. Further, the invention provides an application of the compositions containing the peptide moieties for preventive and/or therapeutic agents for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of peptide moieties as a testing or diagnostic agent or a research agent for such a disease.
Abstract translation: 本发明提供能够抑制程序性细胞死亡1（PD1）信号通路的免疫抑制化合物。 本发明还提供了用于治疗癌症或通过由PD-1，PD-L1或PD-L2诱导的免疫抑制性信号传导引起的免疫增强治疗和用它们的疗法治疗感染的基于组合物，包括作为活性成分的免疫增强底物 。 此外，本发明提供含有肽部分的组合物用于癌症，癌症转移，免疫缺陷，感染性疾病等的预防和/或治疗剂的应用，以及肽部分作为测试或诊断剂或研究的应用 这种疾病的代理人。
-
公开(公告)号：US20140199334A1
公开(公告)日：2014-07-17
申请号：US14124370
申请日：2011-12-21
Applicant: Pottayil G. N. Sasikumar , Muralidhara Ramachandra , Suresh Kumar Vadlamani , K. Rajeev Shrimali , Krishnaprasad Subbarao
Inventor： Pottayil G. N. Sasikumar , Muralidhara Ramachandra , Suresh Kumar Vadlamani , K. Rajeev Shrimali , Krishnaprasad Subbarao
IPC: C07K7/02
CPC classification number: C07K7/02 , A61K38/00 , A61K38/08 , C07K5/0227 , Y02A50/385 , Y02A50/401 , Y02A50/402 , Y02A50/406 , Y02A50/409 , Y02A50/411 , Y02A50/414 , Y02A50/463 , Y02A50/465 , Y02A50/467 , Y02A50/469 , Y02A50/471 , Y02A50/473 , Y02A50/478 , Y02A50/481 , Y02A50/491
Abstract: The present invention provides Immunosuppressive compounds capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The present invention further provides peptide based compositions for treatment of cancer or treatment of infections via immunopotentiation caused by inhibition of immunosuppressive signalling induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient. Further, the invention provides pharmaceutical compositions comprising the Immunosuppressive peptide compounds or modified peptide moieties for preventive and/or therapeutic agents for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of PD-1 or PD-L1 as a testing or diagnostic agent or a research agent for such a disease.
Abstract translation: 本发明提供能够抑制程序性细胞死亡1（PD1）信号传导途径的免疫抑制化合物。 本发明还提供了用于治疗癌症或通过由PD-1，PD-L1或PD-L2诱导的免疫抑制性信号传导引起的免疫增强治疗和用它们的疗法治疗感染的基于组合物，包括作为活性成分的免疫增强底物 。 此外，本发明提供了包含用于癌症，癌症转移，免疫缺陷，感染性疾病等的预防和/或治疗剂的免疫抑制肽化合物或修饰肽部分的药物组合物，以及PD-1或PD-L1作为 测试或诊断剂或这种疾病的研究药物。
-
公开(公告)号：US09783578B2
公开(公告)日：2017-10-10
申请号：US14563568
申请日：2014-12-08
Applicant: Pottayil Govindan Nair Sasikumar , Muralidhara Ramachandra , Suresh Kumar Vadlamani , Koteswara Rao Vemula , Leena Khare Satyam , Krishnaprasad Subbarao , K. Rajeev Shrimali , Sreenivas Kandepu
Inventor： Pottayil Govindan Nair Sasikumar , Muralidhara Ramachandra , Suresh Kumar Vadlamani , Koteswara Rao Vemula , Leena Khare Satyam , Krishnaprasad Subbarao , K. Rajeev Shrimali , Sreenivas Kandepu
CPC classification number: C07K14/001 , A61K38/00 , C07K7/06 , C07K7/08 , C07K9/00 , C07K14/705
Abstract: The present invention provides immunosuppression compounds to inhibit the programmed cell death 1 (PD1) signalling pathway. The present invention further provides peptide based compositions for treatment of cancer or treatment of infections via immunopotentiation caused by inhibition of immunosuppressive signaling induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient. Further, the invention provides an application of the compositions containing the peptide moieties for preventive and/or therapeutic agents for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of peptide moieties as a testing or diagnostic agent or a research agent for such a disease.
-
公开(公告)号：US20150087581A1
公开(公告)日：2015-03-26
申请号：US14563568
申请日：2014-12-08
Applicant: Pottayil Govindan Nair Sasikumar , Muralidhara Ramachandra , Suresh Kumar Vadlamani , Koteswara Rao Vemula , Leena Khare Satyam , Krishnaprasad Subbarao , K. Rajeev Shrimali , Sreenivas Kandepu
Inventor： Pottayil Govindan Nair Sasikumar , Muralidhara Ramachandra , Suresh Kumar Vadlamani , Koteswara Rao Vemula , Leena Khare Satyam , Krishnaprasad Subbarao , K. Rajeev Shrimali , Sreenivas Kandepu
CPC classification number: C07K14/001 , A61K38/00 , C07K7/06 , C07K7/08 , C07K9/00 , C07K14/705
Abstract: The present invention provides immunosuppression compounds to inhibit the programmed cell death 1 (PD1) signalling pathway. The present invention further provides peptide based compositions for treatment of cancer or treatment of infections via immunopotentiation caused by inhibition of immunosuppressive signaling induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient. Further, the invention provides an application of the compositions containing the peptide moieties for preventive and/or therapeutic agents for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of peptide moieties as a testing or diagnostic agent or a research agent for such a disease.
Abstract translation: 本发明提供免疫抑制化合物以抑制程序性细胞死亡1（PD1）信号通路。 本发明还提供了用于治疗癌症或通过由PD-1，PD-L1或PD-L2诱导的免疫抑制性信号传导引起的免疫增强治疗的感染治疗和使用它们的疗法，作为活性成分的免疫增强底物 。 此外，本发明提供含有肽部分的组合物用于癌症，癌症转移，免疫缺陷，感染性疾病等的预防和/或治疗剂的应用，以及肽部分作为测试或诊断剂或研究的应用 这种疾病的代理人。
-
公开(公告)号：US09096642B2
公开(公告)日：2015-08-04
申请号：US14124370
申请日：2011-12-21
Applicant: Pottayil G. N. Sasikumar , Muralidhara Ramachandra , Suresh Kumar Vadlamani , K. Rajeev Shrimali , Krishnaprasad Subbarao
Inventor： Pottayil G. N. Sasikumar , Muralidhara Ramachandra , Suresh Kumar Vadlamani , K. Rajeev Shrimali , Krishnaprasad Subbarao
CPC classification number: C07K7/02 , A61K38/00 , A61K38/08 , C07K5/0227 , Y02A50/385 , Y02A50/401 , Y02A50/402 , Y02A50/406 , Y02A50/409 , Y02A50/411 , Y02A50/414 , Y02A50/463 , Y02A50/465 , Y02A50/467 , Y02A50/469 , Y02A50/471 , Y02A50/473 , Y02A50/478 , Y02A50/481 , Y02A50/491
Abstract: The present invention provides Immunosuppressive compounds capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The present invention further provides peptide based compositions for treatment of cancer or treatment of infections via immunopotentiation caused by inhibition of immunosuppressive signalling induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient. Further, the invention provides pharmaceutical compositions comprising the Immunosuppressive peptide compounds or modified peptide moieties for preventive and/or therapeutic agents for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of PD-1 or PD-L1 as a testing or diagnostic agent or a research agent for such a disease.
Abstract translation: 本发明提供能够抑制程序性细胞死亡1（PD1）信号传导途径的免疫抑制化合物。 本发明还提供了用于治疗癌症或通过由PD-1，PD-L1或PD-L2诱导的免疫抑制性信号传导引起的免疫增强治疗的感染治疗和使用它们的疗法，作为活性成分的免疫增强底物 。 此外，本发明提供了包含用于癌症，癌症转移，免疫缺陷，感染性疾病等的预防和/或治疗剂的免疫抑制肽化合物或修饰肽部分的药物组合物，以及PD-1或PD-L1作为 测试或诊断剂或这种疾病的研究药物。
-
-
-
-
Search Results
5
records
(took 0.011 seconds)
